Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis.
cholangitis
propensity score
quality of life
serum albumin
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
08
02
2022
revised:
10
05
2022
accepted:
08
06
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In this study, we aimed to reevaluate the transition of new symptom development in PBC and its predictive factors. This retrospective multicenter study enrolled 382 patients with PBC for symptom analysis. The impact of a newly developed symptom on PBC prognosis was investigated by Kaplan-Meier analysis with propensity score matching and logistic progression analysis. The cumulative risk of developing a new symptom after 10 and 20 years of follow-up was 7.6 and 28.2%, and specifically that of pruritus, which was the most common symptom, was 6.7 and 23.3%, respectively. In Cox hazard risk analysis, serum Alb level (hazard ratio [HR], 1.097; 95% confidence interval [CI], 1.033-1.165; The cumulative risk of new symptom development is roughly 30% 20 years after diagnosis and could be predicted by factors including serum albumin levels, serum D-Bil level, and Paris II criteria.
Sections du résumé
Background and Aim
UNASSIGNED
Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In this study, we aimed to reevaluate the transition of new symptom development in PBC and its predictive factors.
Methods
UNASSIGNED
This retrospective multicenter study enrolled 382 patients with PBC for symptom analysis. The impact of a newly developed symptom on PBC prognosis was investigated by Kaplan-Meier analysis with propensity score matching and logistic progression analysis.
Results
UNASSIGNED
The cumulative risk of developing a new symptom after 10 and 20 years of follow-up was 7.6 and 28.2%, and specifically that of pruritus, which was the most common symptom, was 6.7 and 23.3%, respectively. In Cox hazard risk analysis, serum Alb level (hazard ratio [HR], 1.097; 95% confidence interval [CI], 1.033-1.165;
Conclusion
UNASSIGNED
The cumulative risk of new symptom development is roughly 30% 20 years after diagnosis and could be predicted by factors including serum albumin levels, serum D-Bil level, and Paris II criteria.
Identifiants
pubmed: 35928695
doi: 10.1002/jgh3.12789
pii: JGH312789
pmc: PMC9344586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
577-586Informations de copyright
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Gastroenterology. 1977 Jun;72(6):1204-7
pubmed: 870368
Hepatology. 2019 Jan;69(1):394-419
pubmed: 30070375
Gastroenterology. 2015 Dec;149(7):1804-1812.e4
pubmed: 26261009
Gastroenterology. 2009 Apr;136(4):1281-7
pubmed: 19208346
Am J Gastroenterol. 2010 Oct;105(10):2186-94
pubmed: 20502446
Hepatol Res. 2014 Jan;44 Suppl S1:71-90
pubmed: 24397841
Gut. 2004 Jun;53(6):865-70
pubmed: 15138215
J Hepatol. 2014 Jun;60(6):1249-58
pubmed: 24548531
J Hepatol. 1994 Jun;20(6):707-13
pubmed: 7930469
Gastroenterology. 2006 Mar;130(3):715-20
pubmed: 16530513
Hepatol Res. 2002 Apr;22(4):250-260
pubmed: 11929710
Dig Dis Sci. 2020 Oct;65(10):3006-3013
pubmed: 31853781
Gastroenterology. 1985 Aug;89(2):267-71
pubmed: 4007417
Hepatol Res. 2021 Feb;51(2):166-175
pubmed: 33126288
Scand J Gastroenterol. 1989 Jan;24(1):57-64
pubmed: 2928724
J Gastroenterol. 2009;44(6):630-4
pubmed: 19370305
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
J Hepatol. 2011 Dec;55(6):1361-7
pubmed: 21703194
Am J Gastroenterol. 1999 Jan;94(1):47-53
pubmed: 9934730
Gastroenterology. 1990 Jun;98(6):1567-71
pubmed: 2338193
Liver. 1999 Apr;19(2):115-21
pubmed: 10220741
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Am J Gastroenterol. 2019 Jan;114(1):48-63
pubmed: 30429590